Article Versions Notes

Xagara A, Roumeliotou A, Kokkalis A, Tsapakidis K, Papakonstantinou D, Papadopoulos V, Samaras I, Chantzara E, Kallergi G, Kotsakis A. ES-SCLC Patients with PD-L1⁺ CTCs and High Percentages of CD8⁺PD-1⁺T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment. Biomedicines. 2024; 12(1):146. https://doi.org/10.3390/biomedicines12010146

Xagara, Anastasia, Argyro Roumeliotou, Alexandros Kokkalis, Konstantinos Tsapakidis, Dimitris Papakonstantinou, Vassilis Papadopoulos, Ioannis Samaras, Evagelia Chantzara, Galatea Kallergi, and Athanasios Kotsakis. 2024. "ES-SCLC Patients with PD-L1⁺ CTCs and High Percentages of CD8⁺PD-1⁺T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment" Biomedicines 12, no. 1: 146. https://doi.org/10.3390/biomedicines12010146

Xagara, A., Roumeliotou, A., Kokkalis, A., Tsapakidis, K., Papakonstantinou, D., Papadopoulos, V., Samaras, I., Chantzara, E., Kallergi, G., & Kotsakis, A. (2024). ES-SCLC Patients with PD-L1⁺ CTCs and High Percentages of CD8⁺PD-1⁺T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment. Biomedicines, 12(1), 146. https://doi.org/10.3390/biomedicines12010146